Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.38 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.38 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains cautiously optimistic about the company's future, emphasizing progress in clinical development. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted ongoing progress in clinical trials.
They expressed confidence in upcoming data releases.
No specific guidance was provided for future quarters.
The earnings report indicates that Protagonist Therapeutics is still in a developmental phase, with no revenue reported. The stock's positive reaction, rising 9.58%, suggests that investors are optimistic about the company's clinical progress and future potential, despite the EPS miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
OCCIDENTAL PETE CORP
Nov 5, 2018